Stock Price Prediction

FULC stock has faced significant challenges, with a 58% drop in the past month due to the failure of its late-stage FSHD drug, losmapimod. However, the company is pivoting to pociredir, a promising sickle cell disease treatment with Fast Track and Orphan Drug designations, which could drive future growth if 2025 trial results are positive. Current valuation metrics suggest the stock is undervalued, trading at a price/book ratio of 0.81, well below the industry average of 3.89.

FULC stock is bearish at $3.96, down 5.26% on January 31, 2025. The 58% drop last month due to a failed drug trial significantly weakened investor confidence. While its sickle cell treatment shows potential, the lack of late-stage candidates delays revenue recovery.

The market consensus for FULC's eps in the upcoming quarter is projected to be approximately $0.27 USD.